Drug Profile
121564
Alternative Names: Compound 121564Latest Information Update: 23 Feb 2022
Price :
$50
*
At a glance
- Originator American University of Beirut Medical Center
- Developer American University of Beirut Medical Center; Merck KGaA
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
Most Recent Events
- 23 Feb 2022 Phase II trial is still ongoing in Non-small cell lung cancer (Early-stage disease, Neoadjuvant therapy, First-line therapy, Combination therapy) in Lebanon (IV) (NCT03480230)